{"name":"Affimed GmbH","slug":"affimed-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AFM 13","genericName":"AFM 13","slug":"afm-13","indication":"Hodgkin lymphoma","status":"phase_1"}]}],"pipeline":[{"name":"AFM 13","genericName":"AFM 13","slug":"afm-13","phase":"phase_1","mechanism":"AFM 13 is a tetravalent bispecific antibody construct that targets CD30 on tumor cells and CD16A on natural killer (NK) cells, enhancing NK cell-mediated cytotoxicity against CD30-positive tumors.","indications":["Hodgkin lymphoma","anaplastic large cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNUDlmLW5YNEdIemJzdFg2SGw3ekFrREczV08ta1VySWZOQ2ZET3h2MFZSeW5Eby1fNzBHc3B0S3Jld1VmRnVfbnlKLUw3dnR3M004OEQyTXVvbjhoUHdlZWNoNzgxbnpWOW8taE1EeFlSeUVSMUVxUU04LTliV0hWY3hNMXRGd1FCMl9zc2c1TXNGWTg?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Segmentation, Major Trends, and Competitive Overview of the Anaplastic Large Cell Lymphoma Therapeutics Market - openPR.com","headline":"Segmentation, Major Trends, and Competitive Overview of the Anaplastic Large Cell Lymphoma Therapeutics Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNWGEwSHd4N0h1cHk2OE1JS1d6Zkg5RUlIYkNyTGZKZkFvNFNGYi1ZZnREWU1oSDUzZ3RoWVI3ZUpXVURTWVpJcmdENE1GNkpnMzBQWERDekZRM0FMTklMR0RCN0NfVFczbE1idlFKMUpSdTNmVjBMUmwtUkxtSG1KUGhNTkxOc0pkWXRGS2RaVzFQcnlPelZjSE45T21QSXVDTFF5SElCRHJhdw?oc=5","date":"2026-04-03","type":"pipeline","source":"Medscape","summary":"Sacral Fracture Risk After Short-Course RT for Rectal Cancer - Medscape","headline":"Sacral Fracture Risk After Short-Course RT for Rectal Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPS3VNanRLNWtia3V0cnZQZTdpUnJHYllYYVJHMGJyNjBuOGpuMUFma2tybGlSM2tDWmNsV05jTU9WQVNydXpqMzRzZWtCaW92bmY2aVV3XzNwTDc0TzBodmJaNTF3X1l1ZG92RGMtblltNlhXSDRTaEs3RjdnSlVEQUF0UFpqeEpad3k1b2ZGSjdnQndNOGtqbXVR?oc=5","date":"2026-03-18","type":"pipeline","source":"openPR.com","summary":"Hodgkin's Lymphoma Pipeline Expands as 15+ Pharma Companies - openPR.com","headline":"Hodgkin's Lymphoma Pipeline Expands as 15+ Pharma Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFBMTXZQQ2MxTTJUYkRLdnROV2xuYWVNYm45dFlSWk15OXZqd0FENy1KeklBNlUzbFNLSjNZRjVsVWF2d05rSlRKUXFwRk9UYXViUzdHZzg4dElSUUNhaTVLNnhJYlk0MjMxQlh3NnNMN0NGT2lHelE?oc=5","date":"2025-09-19","type":"trial","source":"Oncology Pipeline","summary":"What now for NK-cell engagers? | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"What now for NK-cell engagers? | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNSWVpczNQT2txOERNaEpmTzFCd3pqRGNmY1RPekRMTVF0VmVXQUNrR1NyZlgyX0RoODZabHhackJpMnhxOWpsd3N6bWkzRWxmTXhWd25ScElPZkF0VXV2RHVuR3F5d3l0RzdvbXk0ejg5Zm1KSmd1UkxUZzEwYnEyazdBREZ0OTBqWklxaU5TUEUzekV6Mk1OQXFLeHd3eFJIdGJXSW5HYVhNeGotbnNzcHNhSWIxYTJrdnpUNU1OenprTXBxa1dFMUQ1dXZ6TVl1Z051dg?oc=5","date":"2025-05-13","type":"pipeline","source":"GlobeNewswire","summary":"Affimed Announces Filing for the Opening of Insolvency Proceedings - GlobeNewswire","headline":"Affimed Announces Filing for the Opening of Insolvency Proceedings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE8zTmtaYjFhZWJ2bVlyVmk2c0t6bWVWMmwyRWQ5WWpiZHdFRVFfZUdQeVJXY0FndDBuNXFmbXh6ZTR6NVpIeXBxcnc2c2txZy00SXlF?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"AFMD Stock Price, News & Analysis - Stock Titan","headline":"AFMD Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"prnewswire.com","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - prnewswire.com","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9uZ0ZBc21GVnBqekNtam8waDl5UE5RdDdpdWF4SW1tOGxXa1dqU3I0OHZLSWJIWUNjT2h2UmxKMi1HbGxQbExrV2VlR19EU0taZTh5akRCUXFRNXcxQV9KNWdITG03UXVfUVdYVGlqQkJOdU5xSU03b0Uwcw?oc=5","date":"2019-12-09","type":"pipeline","source":"acsjournals.onlinelibrary.wiley.com","summary":"The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management - acsjournals.onlinelibrary.wiley.com","headline":"The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}